Lymphoma Clinical Trials

Showing 1601-1620 of 1,633 trials

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

NCT00955786

This phase 1 study of CX-3543 is designed to test the safety, tolerability and highest safe dose level of this drug in patients with advanced solid tumor cancers.

Advanced Solid TumorsLymphoma

Cylene Pharmaceuticals48 participantsStarted Jul 2005

Scottsdale, Arizona, United States • San Antonio, Texas, United States

COMPLETEDPhase 2

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

NCT00210379

The primary objective assess the clinical activity of combination doxorubicin-containing chemotherapy plus monoclonal antibody anti-CD20 (Rituximab) plus intrathecal prophylactic chemotherapy and loco-regional radiotherapy in primary localised testicular DLCL and to assess the toxicity of this therapeutic strategy

Lymphoma, B Cell

International Extranodal Lymphoma Study Group (IELSG)64 participantsStarted Nov 2000

Bellinzona, Switzerland

UNKNOWNPhase 1

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00053105

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.

Lymphoma

TheradexStarted Feb 2002

Tucson, Arizona, United States • Springdale, Arkansas, United States • Los Angeles, California, United States +4 more locations

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Related Searches

Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy

Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies

High-Dose Therapy Treatment in Patients With Follicular Lymphoma

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

Phase I Study of Intrathecal Topotecan

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)